October 19th, 2010 by KerriSparling in Better Health Network, Health Policy, Medblogger Shout Outs, News, Opinion, True Stories
No Comments »
I was in Las Vegas, but it wasn’t all just spending quality time with blogging buddies. There was work to do — we were there for the Social Health track of BlogWorld & New Media Expo 2010 to help inform others about the discussions taking place in the medical blogosphere, and the power of these communities.
The panel that I was participating on was Social Networks & The Medical Blogosphere: Compatible or Competitive, with fellow panelists Kevin Pho and Bryan Vartabedian (see photo) moderated by the fabulous Kim McAllister. The big question was: “Are these social networking technologies helping or hurting the blogosphere?”
We, as a panel, gave this a lot of thought as we prepared for our discussion, and we ultimately settled on the answer of “Well…both.” Read more »
*This blog post was originally published at Six Until Me.*
October 15th, 2010 by Bryan Vartabedian, M.D. in Better Health Network, Opinion
No Comments »
[Recently] some of us participated in the flagship physician Tweetchat (MDChat). Or better, I tried to participate between finishing up some calls and choking down a bean burrito.
When the idea was initially proposed to me I committed only to supporting its initiation with the occasional role of host. I’m simply overcommitted, but wanted to support Phil Baumann and those who were willing to try to break new ground. So I lurked, chewed, and pondered.
Doctors or not, everyone knows I’ve been a pretty lukewarm proponent of the tweetchat. I think they’re noisy, difficult to follow, and too abbreviated for constructive dialog. As early adopters I think we tend to put the novelty of the medium above its practicality.
With that said, chats can be fun. It’s a situation where I feel comfortable while at once restless. Kind of like at a medical staff meeting where the agenda doesn’t hold me quite as much as just being among my friends.
At the end of the day I might agree with Dr. Anonymous that the average physician new to social media might not find a twitter chat as the best way to spend a precious hour. For me that hour represents the better part of a blog post which, over the course of a month, will influence hundreds of readers and live forever.
But I suspect that there will always be those among us looking for companionship over content. And it’s hard to argue with that.
*This blog post was originally published at 33 Charts*
October 11th, 2010 by DavedeBronkart in Better Health Network, Health Policy, Opinion
1 Comment »
Last month in Cambridge I met Twitter friend Bryan Vartabedian, M.D. (Twitter @Doctor_V) at a meeting at Vertex Pharmaceuticals. We’ll cross paths this fall on the conference speaking circuit. [Recently] on his blog he raised a rowdy, rough, but valid point: As e-patients (obviously including me) get into the business, should they/we be regulated? He said:
Will industry be required to publicly list monies used for sponsorship, travel and swag support of high profile patients in the social sphere?
Should high visibility patients who serve as stewards and advocates disavow themselves of contact with pharma just as many academic medical centers have begun?
As is often the case, I don’t have an answer. I’m just raising the questions. Smart questions. My short answer:
- Fine with me if industry discloses those payments. Nothing to hide.
- On the other hand, I think it’s nuts and counterproductive for consumers in any industry to disconnect.
Academic medical centers have tons of evidence of influence corrupting the academic processes that are at the core of (supposed) science. For patient advocates I don’t see that there’s currently a problem that would justify adding regulators, the ensuing budget impact, etc.
Besides, there’s a key difference: Academics are supposed to vet industry. It’s their job in this context. Patients, on the other hand, are the consumers — the ones the industry’s supposed to serve. Read more »
*This blog post was originally published at e-Patient Dave*
October 8th, 2010 by Bryan Vartabedian, M.D. in Better Health Network, Medblogger Shout Outs, News, Opinion, Research
No Comments »
I [recently] received a press release from a friend in the Bay Area. Investigators at UCSF have published a study in the New England Journal of Medicine showing that less chemotherapy can be effective at treating some childhood cancers.
The paper was the result of an eight-year clinical study in children with neuroblastoma. In this particular population, researchers were able to reduce chemotherapy exposure by 40 percent while maintaining a 90 percent survival rate. You can read about it here.
The press release sparked a brief email exchange between me and my friend: Who might be interested in writing about this study and is there any way to get it to spread? What would make it sticky in the eyes of the public?
Here are a few ideas:
Figure out who cares. Sure it’s niche news, but there are people who would think this is pretty darn important. Think organizations centered on parents of children with cancer, adult survivors of childhood cancer, pediatric hematology-oncology physicians, pediatricians and allied professionals in pediatric medicine like nurse practitioners and hematology-oncology nurses. Networks form around these groups. Find them and seed them.
Make a video. Offer powerful, visual content beyond a press release. A four-minute clip with the principal investigator, Dr. Matthay, would be simple and offer dimension to what is now something restricted to print. The Mayo Clinic has done this really well. Read more »
*This blog post was originally published at 33 Charts*
October 4th, 2010 by Bryan Vartabedian, M.D. in Better Health Network, Health Policy, Opinion
No Comments »
Patients are the new darling of the medical-industrial complex. If you look around you will see patients advocating for one another. If you click a little closer you’ll find some with relationships to industry.
It makes perfect sense that the manufacturer of a drug or medical device would want the blessings of our nascent cybercelebs. Some want genuine patient input. Some, however, want to curry their favor. Chock up influence of the patient population as evidence of social health’s evolving maturity.
A couple of questions:
- Will industry be required to publicly list monies used for sponsorship, travel and swag support of high profile patients in the social sphere?
- Should high visibility patients who serve as stewards and advocates disavow themselves of contact with pharma just as many academic medical centers have begun?
As is often the case, I don’t have an answer. I’m just raising the questions. Read more »
*This blog post was originally published at 33 Charts*
